FMP
Decibel Therapeutics, Inc.
DBTX
NASDAQ
Inactive Equity
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
4.91 USD
-0.04 (-0.815%)
Dr. Laurence E. Reid Ph.D.
Healthcare
Biotechnology
NASDAQ
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
0001656536
US24343R1068
24343R106
1325 Boylston Street
617 370 8701
US
68
Feb 12, 2021
Ms. Elaine Cope M.B.A.
Vice President of Operations
0
N/A
Dr. Laurence E. Reid Ph.D.
Pres & Chief Executive Officer
742.98k
1964
Mr. M. Charles Liberman
Co-Founder & Member of Scientific Adviso...
0
N/A
Dr. Albert S. B. Edge
Co-Founder & Member of Scientific Adviso...
0
1955
Ms. Elaine Cope
Vice President of Operations
0
N/A
Dr. Gabriel Corfas
Co-Founder & Member of Scientific Adviso...
0
N/A
Dr. Ulrich Müller
Co-Founder & Member of Scientific Adviso...
0
N/A
Mr. James B. Murphy
Interim Chief Financial Officer, Princip...
0
1957
Ms. Anna Trask M.A.
Executive Vice President & Chief People ...
481.23k
1958
Mr. John J. Lee
Executive Vice President & Chief Devel. ...
596.15k
1968
Mr. Geoff Horwitz
Vice President of Corporation Devel. & H...
0
N/A
Mr. Joe Burns Ph.D.
Senior Vice President of Discovery
0
N/A
As of December 31, 2024, the total employee count stands at 68, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.